Cite
APA Citation
Goy, A., Forero, A., Wagner‐Johnston, N., Christopher Ehmann, W., Tsai, M., Hatake, K., Ananthakrishnan, R., Volkert, A., Vandendries, E., & Ogura, M. (2016). a phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British journal of haematology, 174, 571–581. http://access.bl.uk/ark:/81055/vdc_100035003993.0x000055